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Conclusions: In the majority of patients with progressive 
CRPC and a symptomatic pelvic tumor, PPRT with 30-39 Gy 
contributes to relief of macroscopic hematuria, pain and 
other pelvic symptoms as well as improved QOL, with little 
toxicity. Future studies should investigate whether PPRT 
regimens can be further simplified.  
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Purpose/Objective: The therapeutic ratio of antalgic 
radiotherapy for bone metastases might be improved by 
decreasing the radiotherapy dose to the normal tissue and/or 
by increasing the dose to the bone metastases. A three arm 
randomized phase II trial comparing single fraction 
conventional radiotherapy with 2 different dose levels of 
single fraction Biological Image Guided Stereotactic 
RadioSurgery (BIG-SRS) will allow us to select the treatment 
arm with sufficient promise of efficacy to justify its 
evaluation in a definitive phase III trial. 
Materials and Methods: Patients with painful bone 
metastases without major neurological symptoms were 
enrolled. All patients underwent a 18[F]-FDG-PET-CT prior to 
irradiation. Patients were randomized (1:1:1) to receive 
either 8 Gy in a single fraction with conventional 
radiotherapy (arm A) or 8 Gy in a single fraction with dose-
painting-by-numbers (DPBN) (dose range between 6 and 10 
Gy) (arm B) or 16 Gy in a single fraction with DPBN (dose 
range between 14 and 18 Gy) (arm C). The primary endpoint 
was overall pain response at 1 month, defined as the sum of 
complete and partial pain responses to treatment assessed 
using a visual analogue scale (range 0-10). Analysis was done 
by intention to treat and pairwise tests are based on a score 
statistic and Fisher's information pairs. The arm with the 
highest score statistic is selected as the most promising to 
continue in phase III. 
Results: 
 
Forty-five patients were randomized to a treatment group. 
Eight patients (53%), 12 patients (80%) and 9 patients (60%) 
had an overall response to treatment in arm A, B and C, 
respectively. The estimated odds ratio of arm A vs B is 3.5 
(95% CI: 0.44-17.71) with a score statistic of 2.4 (p = 0.12). 
Patients in Arm B showed a significant improvement in QOL 
score at 1 month compared with Arm A (pain characteristic, 
insomnia and appetite loss, p<0.05). The estimated odds 
ratio of arm A vs C is 1.31 (95% CI: 0.31-5.58) with a score 
statistic of 0.14 (p = 0.71). No differences in QOL between 
Arm A and C were observed. 
Conclusions: A single fraction of 8 Gy by means of BIG-SRS 
shows a promising overall pain response of 80%, meriting 
further evaluation in phase III.  
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Purpose/Objective: In contrast to patients with early stage 
NSCLC, clear recommendations are still missing for SBRT for 
lung metastases regarding patient selection, planning, 
delivery, dose and quality assurance. This report of the 
German working group stereotactic radiotherapy pools SBRT 
patient data of German centers and aims to describe local 
control, overall survival, prognostic factors and dose 
recommendations in respect to the different primary 
subgroups. 
Materials and Methods: All radiotherapy departments in 
Germany were contacted and invited to participate in this 
study. 700 patients with 963 lung metastases treated with 
SBRT were included in this database. The analyzed subgroups 
were NSCLC (25.7%), colorectal cancer (22.6%), renal cell 
cancer (6.7%), breast cancer (6.2%) and sarcoma. 30% of the 
lesions were treated as single fraction radiosurgery, 36% in a 
three fraction approach, 34% lesions with different 
fractionation.  
Results: Median follow-up time was 26.4 months. For the 
entire patient cohort, an excellent local control rate after 1 
year of 90.8% and after 2 years of 81.4% was detected. In 
detail, the best 1-year- and 2-year-local control rate was 
achieved for breast cancer (97.5% vs. 97.5%), followed by 
renal cell carcinoma (96.2% vs. 93.3%), NSCLC (94.7% vs. 
76.2%), colorectal cancer (88.3% vs. 81.2%) and sarcoma 
(68.7% vs. 45.8%). For the entire patient cohort, local control 
was significantly influenced by primary tumor histology, 
Karnofsky performance scale, localization (central vs. 
peripheral), time of metastases detection (synchronous vs. 
metachronous) and maximum tumor diameter. 2-year overall 
survival rates were 64.5% for breast cancer, 66.1% for 
colorectal cancer, 62.7% for renal cell carcinoma, 54.7% for 
NSCLC and 39.1% for sarcoma. Additionally, conducting 
biological modeling we tried to propose primary specific dose 
recommendations needed for 90%-2-year-local control for the 
different tumor entities (e.g. BED= 97.5 Gy for NSCLC vs. BED 
= 108.8 Gy for colorectal cancer). 
Conclusions: SBRT for lung metastases from different 
primary tumors was effective and safe despite considerable 
interinstitutional variability in SBRT practice throughout 
Germany. Prognostic factors and doses for 90%-local control 
are truly dependent on the different primary tumors. Future 
prospective studies are of highly interest to evaluate dose 
recommendations and prognostic factors. 
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Purpose/Objective: Many head and neck cancer survivors 
experience reduced quality of life due to radiotherapy-
related dysphagia and swallowing exercises have been 
suggested as an option for treatment hereof. The aim of this 
meta-analysis was to evaluate the impact of prophylactic 
swallowing exercises on swallowing-related outcomes in head 
and neck patients treated with curative radiotherapy.  
Materials and Methods: Pubmed was searched for 
publications up to Oct 30th 2014 on subject headings for the 
following concepts: swallowing exercises, dysphagia 
rehabilitation, radiotherapy and head and neck cancer; all 
reference lists in the selected journal articles were 
additionally screened for potentially relevant articles. 
Included papers contained information on objective 
endpoints (N=4), observer-rated endpoints (N=8), patient-
rated endpoints (N=5), clinical endpoints (N=10) or a 
combination of these. A meta-analysis of PEG tube incidence 
was performed using 'Comprehensive Meta-analysis'; a p value 
≤ 0.05 was considered significant. 
Results: A total of 12 papers were included. In general, most 
of the studies reported some positive results of swallowing 
therapy but a comparison was complicated by the broad 
range of interventions, evaluation times and endpoints used 
and the benefit was not consistent and not related to specific 
measures.  
Incidence of PEG tube was the endpoint most often reported 
(N=9) and the only endpoint suited for meta-analysis. In the 
current setting, four studies reported a benefit from 
prophylactic exercises and five studies reported no difference 
on PEG tube incidence. A meta-analysis of these studies 
regardless of evaluation time and design (Figure 1) showed an 
overall benefit of prophylactic exercises with an odds ratio of 
0.30 (95% CI: 0.21-0.44). This benefit remained if only 
randomized controlled trials (RCTs) or studies examining 
incidence of tube feeding ≥ 6 months post-treatment was 
used. 
 
 
Conclusions:  
The meta-analysis showed a positive impact of prophylactic 
swallowing exercises on PEG tube incidence; it was not 
possible to examine other endpoints in this meta-analysis due 
to heterogeneous use of evaluation methods and scales. 
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Purpose/Objective: To determine the maximum tolerated 
dose (MTD) of an hypofractionated accelerated IMRT 
treatment with the simultaneous integrated boost (SIB) 
technique in patients with < 5 brain metastases.  
Materials and Methods: Patients with < 5 brain metastases 
and no extra-cranial disease were enrolled in a phase I study. 
IMRT was delivered over 2 weeks in 10 fractions to the two 
planning target volumes (PTVs) defined by adding 5-mm 
margin to the respective clinical target volumes (CTVs). The 
CTV1 was defined as each single lesion (GTV) on the basis of 
